Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success
Regeneron $REGN and Alnylam $ALNY have laid a foundation for an enduring R&D alliance that could go out well past a decade, with billions of dollars on the line if they’re successful.
We already know that Regeneron is paying $800 million for the upfront and equity stake, with another $200 million for proof-of-principle milestones — which we’ve noted makes it one of the top platform deals in industry history.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
